Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Lora Dillinger

Nurse Practitioner, Gerontology Wyomissing, PA Nurse Practitioner

NPI 1669926283 CMS profile 11104429

2608 Keiser Blvd, Wyomissing, PA 19610

Open in the dashboard

General payments

$20,896

988 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lora Dillinger of Wyomissing, PA is reported in the CMS Open Payments database as having received $20,896 across 988 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Gerontology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,381 149
2024 General $3,286 144
2023 General $4,629 196
2022 General $7,372 386
2021 General $2,229 113

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lora Dillinger
  • Nurse Practitioner, Gerontology median
  • Middle half of Nurse Practitioner, Gerontology
  • National median

In program year 2025, general payments to Lora Dillinger were reported at $3,381. Among 4,139 Nurse Practitioner, Gerontology profiles paid that year, the median was $179 and the middle half received between $55 and $547.

Show as a table
Year Lora Dillinger Nurse Practitioner, Gerontology median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $2,229 $133 $44–$396 $132
2022 $7,372 $142 $48–$452 $149
2023 $4,629 $158 $53–$482 $160
2024 $3,286 $171 $55–$533 $164
2025 $3,381 $179 $55–$547 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $3,962 130 payments
  2. GlaxoSmithKline, LLC. $3,011 151 payments
  3. Baxter Healthcare $2,644 154 payments
  4. Jazz Pharmaceuticals Inc. $1,729 84 payments
  5. Harmony Biosciences LLC $1,411 66 payments
  6. Genzyme Corporation $906 42 payments
  7. Regeneron Healthcare Solutions, Inc. $729 41 payments
  8. Axsome Therapeutics, Inc. $650 32 payments
  9. Philips Electronics North America Corporation $497 21 payments
  10. Mylan Specialty L.P. $470 31 payments
  11. Other $4,889 236 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $20,375 981 payments
  2. Education $521 7 payments
Products named General payments · program years 2021–2025
  1. FASENRA $2,079 52 payments
  2. BREZTRI $1,882 43 payments
  3. TRELEGY ELLIPTA $1,675 91 payments
  4. Hillrom - Life 2000 Ventilation System $1,382 90 payments
  5. TEZSPIRE $1,355 19 payments
  6. XYWAV $1,218 54 payments
  7. DUPIXENT $1,142 45 payments
  8. NUCALA $1,106 68 payments
  9. AIRSUPRA $919 5 payments
  10. Hillrom - Vest System Model 105 Home Care $735 43 payments
  11. Other $11,130 517 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

377

Median for Nurse Practitioner: 389

Drug cost

$137,968

Median for Nurse Practitioner: $21,885

Branded share of claims

72.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 67 $70,065
Breo Ellipta Fluticasone/Vilanterol Brand 52 $29,737
Spiriva Respimat Tiotropium Bromide Brand 18 $11,392
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 12 $8,292
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 16 $8,243
Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate Brand 14 $3,942
Symbicort Budesonide/Formoterol Fumarate Brand 13 $3,298
Albuterol Sulfate Hfa Albuterol Sulfate Brand 83 $2,509
Montelukast Sodium Generic 22 $290
Prednisone Generic 61 $123

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$34,909

Medicare's payments for the services billed

Medicare patients

307

Average age 72

Services billed

895

151 women, 156 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Ischemic heart disease 37%
Depression 33%
Diabetes 31%
Atrial fibrillation 27%
Chronic kidney disease 24%
Heart failure 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
WAKIX
$428 — —
DUPIXENT
$403 — —
TRELEGY ELLIPTA
$237 67 —
NUCALA
$224 — —
Sunosi
$207 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

988 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Gerontology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record